Jefferies Downgrades Doximity (NYSE: DOCS): Mixed Financial Results and AI Investment Impact Healthcare Technology Stock

• Jefferies downgraded Doximity (NYSE: DOCS) due to a cautious outlook on its short-term potential.
• The company reported mixed financial results, with earnings per share (EPS) missing estimates but revenue growth exceeding expectations.
• Increased AI investment led to higher costs and a slight dip in gross margin, despite strong free cash flow and user engagement.

On May 14, 2026, the firm Jefferies downgraded Doximity (NYSE: DOCS) from Buy to Hold, with the stock priced at $23.39. Doximity is a digital platform for U.S. medical professionals, providing them with clinical workflow tools and a professional network. This stock downgrade reflects a more cautious view of the stock's short-term potential.

This change in rating comes as Doximity reported mixed financial results. As highlighted by Zacks, the company's earnings per share (EPS) of $0.26 for the fourth quarter missed analyst estimates of $0.28. This figure is also lower than the $0.38 per share earned in the same quarter a year ago.

The lower profitability is partly due to a new strategy. Doximity is in an "AI investment year," increasing its spending on new technology. This has caused its non-GAAP gross margin, a key measure of profitability, to fall to 89% from 91% a year earlier due to higher AI-related costs.

Despite the earnings miss, the company's revenue performance was strong. Doximity posted quarterly revenues of $145.37 million, which surpassed market expectations. For the full fiscal year 2026, revenue grew by 13% to $645 million, showing that the company is still expanding its sales in the healthcare technology sector.

Operationally, Doximity shows signs of strength. It generated a record $107 million in quarterly free cash flow, which is the cash left over after paying for operations and investments. As reported by Business Wire, user engagement also reached a new high with over 800,000 active prescribers using its tools, solidifying its position as a leading platform for medical professionals.